Trial reportAntimicrobial agents and chemotherapy2024
Characterization of
Trial report in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Resistance ofPathogens (Basel, Switzerland) · 2025Pooled it
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Disarming carbapenemase-producingAntimicrobial agents and chemotherapy · 2026Article
- Successful Use of Sulbactam-Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report.The American journal of case reports · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Successful Treatment of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Microbiological eradication of XDRFrontiers in medicine · 2026Article
- Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.Antimicrobial agents and chemotherapy · 2025Review
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
- AMRrounds: Carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) ofAntimicrobial agents and chemotherapy · 2025Article
- Review
- Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.